Background: Total tau (T-tau) and b-amyloid (Ab 1-42 ) levels in cerebrospinal fluid (CSF) can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-dementia. Differential diagnosis from dementia with Lewy bodies (DLB) in clinical settings is difficult. Methods: The analytical performance of the INNO-TEST ᮋ PHOSPHO-TAU (181P) assay was validated in terms of selectivity, sensitivity, specificity, precision, robustness, and stability. Clinical utility of the assay alone, or combined with T-tau and Ab 1-42 , for discrimination of AD (ns94) from patients suffering from DLB (ns60) or from age-matched control subjects (CS) (ns60) was assessed in a multicenter study. Results: CSF concentrations of tau phosphorylated at threonine 181 (P-tau 181P ) in AD was significantly higher than in DLB and CS. Discriminant analysis, a classification tree, and logistic regression showed that P-tau 181P was the most statistically significant single variable of the three biomarkers for discrimination between AD and DLB. Conclusions: P-tau 181P quantification is a robust and reliable assay that may be useful in discriminating AD from DLB.
Introduction
Alzheimer's disease (AD) can be considered the most important neurodegenerative brain disease because of its frequent occurrence and devastating consequences, affecting up to 10% of the population older than 65 years. Its impact is increasing in parallel with the general worldwide aging of the population. Histologically, brains of AD patients are characterized by the presence of neurofibrillary tangles (NFT), senile plaques, and synapse loss (1) . The major component of the NFT structures is hyperphosphorylated tau protein. Tau protein is a normal brain phosphoprotein that binds to microtubules in neuronal axons, thereby promoting neural assembly and stability. When hyperphosphorylated, tau loses its stabilizing function, resulting in axon instability and reduced intracellular transport. More than 70 potential phosphorylation sites have been identified in the tau molecule (2) . Tau and phospho-tau are closely associated with the pathology of several age-related neurodegenerative disorders, such as AD, frontotemporal lobe dementia (FTD), and dementia with Lewy bodies (DLB). More reliable diagnostic procedures are required, since AD is only correctly diagnosed in clinical settings in 65%-90% of cases (3) . The higher percentage is especially associated with academic settings with clinical follow-up, while the lower figure more likely occurs in non-academic settings and at first clinical work-up. Consensus criteria for AD biomarkers have been published (4) .
Earlier studies indicated that tau phosphorylated at threonine 181(P-tau 181P ) in cerebrospinal fluid (CSF) might be used to discriminate AD from DLB (5) . Since distinction of AD from DLB is difficult in clinical settings, but important for patient management, as the treatment strategies are different, P-tau 181P determination may prove to be of clinical value. In addition, combined measurement of b-amyloid (Ab ) and P-tau 181P levels has been shown to differentiate AD from FTD (6) .
We describe the performance characteristics of the INNOTEST ᮋ PHOSPHO-TAU (181P) assay and an evaluation of its clinical utility, alone or combined with total tau (T-tau) and Ab for the discrimination of AD from DLB and control subjects (CS).
Materials and methods

Assays
The INNOTEST ᮋ PHOSPHO-TAU (181P) assay is a solid-phase enzyme immunoassay in which P-tau protein is captured by monoclonal antibody (mAb) HT7 (Innogenetics, Gent, Belgium). A sample of 75 mL of undiluted CSF is added and incubated overnight at 2-88C with 25 mL of the biotinylated anti-P-tau 181P mAb AT270 (Innogenetics). Any antigen-antibody complex formed is then detected by peroxidaselabeled streptavidin (SV-PO). Two wash steps are included in the test instructions: one after incubation of the antigen and biotinylated detector antibody, and the other after SV-PO. No difference was observed between a manual wash procedure or an automated wash procedure on a Columbus instrument (data not shown). The assay contains a sample addition monitoring system to confirm the addition of CSF or SV-PO. A phosphorylated peptide, containing both the epitope of HT7 (epitope P 159 PGQK 163 , numbered according to the longest tau isoform) (7) and AT270 (epitope P 176 PAPKTP 182 ), was used for calibration (peptide sequence, acetyl-P 154 RGAAPPGQKGQANATRIPAKTPPAPKTPPSSGE 187 ; molecular weight, 3455 Da; obtained from Neosystems, Strasbourg, France). The calibrator peptide should be considered as a reference standard. Its structure and size differ from the size of the native P-tau protein. The assay format quantifies all tau isoforms phosphorylated at threonine 181. Full details of the assays used in the present study have been described previously (8) (9) (10) .
Production process
Plate coating
The process of mAb coating of immunoplates (Nunc Maxisorpsீ, San Diego, CA, USA) was fully validated. The homogeneity of the mAb coating was verified for each production run by performing an assay with 125 pg/mL of the calibrator peptide. For this purpose, immunoplates were assembled containing 8-well strips obtained from plates selected over the whole production run. Two combined plates were used for testing. Half of the plate (either the upper or lower part) was filled with 125 pg/mL of the calibrator (positive sample) or the blank (negative sample). The percentage coefficient of variation (%CV) for the 96 positive samples was calculated. The effect of the blocking and fixation stabilization process on P-tau 181P concentrations measured in CSF was verified for 38 CSF samples (concentration range 3.5-207.4 pg/mL; calculated on fresh plates) by comparison of results obtained on fresh and stabilized immunoplates, as assessed by a paired two-tailed t-test on log-transformed values.
Stability
The stability of the whole kit was evaluated on kits from two production runs. All components of the kit were stored at 2-88C for more than 24 months. Calibrator peptides were stored at 2-88C or y208C. At each time point, assays were performed according to the test instructions. Three control samples (run validation samples) were prepared by addition of calibrator peptides to artificial CSF (ACSF) (composition NaCl, 138 mM; KCl, 2.8 mM; CaCl 2 Ø2H 2 O, 1.05 mM; MgCl 2 Ø6H 2 O, 1.15 mM; NaH 2 PO 4 ØH 2 O, 1.25 mM; glucose, 0.06% w/w; and human serum albumin, 0.16% w/w).
The effect of freezing (up to ten times) on the prepared calibrator concentration range was also evaluated. At each time point, three aliquots of each calibrator concentration were taken and analyzed on two different mAb-coated plates. Each vial was stored for at least 1 day after each freezing cycle at y208C. All samples were analyzed in the same experiment.
Analytical performance
Curve fitting Experiments were performed to select the most appropriate mathematical model for curve fitting, as well as the number and concentration of dilutions. A lack-offit test determined whether the predicted sigmoidal calibration curve adequately described the data obtained. Evaluation was performed based on model fit (R 2 values), residual analysis, and analysis of the variability on inverse prediction (e.g., estimating concentrations for unknown samples).
Selectivity and specificity Selectivity (ability of the assay to measure and differentiate P-tau 181P in the presence of matrix components that may be expected to be present) and specificity (detection of P-tau 181P as opposed to other P-tau proteins) were evaluated using synthetic biotinylated peptides (sequence Q 165 ANATRIPAKTPPAPKTPPSSGEPPKS 191 ) either phosphorylated at Thr 181 or non-phosphorylated. For this purpose, SV-coated immunoplates were first incubated for 1 h with biotinylated peptides. After a wash step, mAbs were incubated overnight at 2-88C. Detection of the bound mAbs was achieved using peroxidase-labeled goat antimouse antibodies (Jackson Immunoresearch Laboratories, Lucron Bioproducts; De Pinte, Belgium).
Analytical sensitivity Blank samples (bl) (;sample diluent) were used to calculate the limit of detection (LOD; mean bl q2 SD bl ) and lower limit of quantitation (LLOQ; mean bl q10 SD bl ). The upper limit of quantitation (ULOQ) was determined from linearity and accuracy results.
Accuracy Using data from the precision experiments, the percentage bias (known value-predicted value/known value=100%) was calculated. However, in principle, accuracy (closeness of test results obtained by the method to the true concentration of the analyte) was difficult to define in this case, since no reference material (gold standard) is currently available.
Repeatability and reproducibility
Intermediate precision (closeness of individual measurements of an analyte when the procedure is applied repeatedly) was evaluated by the analysis of 12 samples (including six points for calibration and two blanks) for eight replicates on three coated ELISA plates from five different production runs. For each plate and sample, the average, SD, CV, and bias were calculated using the calibrator curve provided in the kit.
Repeatability and reproducibility were tested according to ISO 5725-2 guidelines (11). Control samples were analyzed by three different operators in quadruplicate, using three different vials of calibrators on ELISA plates from the same production run (repeatability), or by one operator in quadruplicate using the same calibrators on plates from three different production runs (reproducibility). The method performance chart presents inaccuracy (percentage bias) plotted against the imprecision (CV).
Linearity Assay linearity (ability of the method to elicit test results that are directly proportional to the analyte concentration) was evaluated by combining samples with high or low concentrations of P-tau 181P in different volume ratios (1:0, 0.75:0.25, 0.5:0.5, 0.25:0.75 and 0:1). Results calculated for the mixed samples were plotted against predicted concentrations obtained in undiluted CSF.
Test robustness
The robustness (capacity of the assay to remain unaffected by deliberate variations in method parameters) or effect of variation in test parameters (antigen and detector-antibody incubation time; SV-PO incubation time, SV-PO incubation temperature, substrate incubation time, and substrate incubation temperature) on assay performance was characterized by factorial design of experiments. In a full factorial design, all combinations of boundary assay parameter settings were tested on ACSF samples, spiked with different concentrations of P-tau 181P -peptide (Table 1 ). Each sample was tested in quadruplicate.
CSF sample preparation To assess the effect of centrifugation, CSF samples (ns15, concentration range 20-160 pg/mL P-tau 181P ) were either aliquoted immediately after collection and stored at y808C, or centrifuged at 2000 g for 10 min at 48C and subsequently frozen at y808C. A Wilcoxon matched-pairs test was used to compare both methods.
To assess the effect of storage conditions, CSF samples (ns11) were aliquoted and stored immediately at y808C, or stored for 4, 24, or 72 h at 48C or at room temperature before freezing at y808C. Repeated-measures ANOVA was used to evaluate the effects of temperature storage conditions.
To evaluate the impact of freezing, CSF samples (ns8) stored at y808C were thawed and refrozen several times. Each CSF sample was stored at y808C for at least 1 night. The effect of additional freezing of CSF was evaluated by repeated-measures ANOVA.
Clinical utility using stored patient samples Samples
The multicenter study used previously stored CSF samples available for research purposes from five laboratories. No follow-up samples were included in the study. Patients suffering from relevant concomitant diseases, such as brain tumors or metastases, CSF infection or stroke, were excluded. The AD group (ns94) consisted of randomly selected patients diagnosed with probable AD according to DSM-IV criteria and criteria established by the work group of the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (12) . DLB patients (ns60) were randomly selected and diagnosed according to the criteria of McKeith et al. (13) . Mini-mental state examination (MMSE) (14) scores were documented for most patients and for some of the CS. Clinical diagnosis preceded or coincided with CSF collection. CS (ns60) were defined as either (i) apparently healthy (ns37) or (ii) subjects without systemic inflammatory or central nervous system disorders, aged over 55 years, who had undergone lumbar puncture and CSF collection for diagnosis of mechanical problems (ns6; 2 nucleopathies, 1 headache in epilepsy, 1 disk herniation, 1 cervical lumbar arthrosis, 1 minor head trauma) or (iii) depression (ns17). Only CSF samples collected in the 2 years preceding the study start, stored in polypropylene tubes, and kept (pending biochemical analysis) frozen at y208C or lower were included. The number of freeze/thaw cycles was recorded.
All clinical samples were tested in duplicate at the respective centers (multicenter collection and testing). Operators were blinded to the expected test outcome in terms of clinical diagnosis. Concentrations of P-tau 181P , T-tau, and Ab were required for all samples. When historical results of INNOTEST ᮋ hTAU Ag and INNOTEST ᮋ b-AMYLOID assays were available, the investigator was free to decide whether or not to repeat these analyses. As such, results for T-tau and Ab 1-42 need to be interpreted with some caution, as they were partly based on historical results not obtained in the standardized protocol setting. The study presented no risk(s) or harm to the subjects. Previously stored samples available for research purposes were used for this study. Ethics Committee approval to conduct the study was not required for three centers, was obtained in one center for research purposes, and was given for the fifth center. Subject confidentiality was maintained at all times, within the legal context of the country, by removal of all direct subject identifiers from patient samples and clinical documentation submitted for this study. Anonymity was also assured in any report or publication.
Statistics
Several statistical techniques wreceiver operating characteristic curve (ROC) analysis, discriminant analysis, classification tree, and logistic regressionx were used in an attempt to optimally classify AD, DLB, and CS in the correct group based on biomarker information. Transformed variables were employed if this resulted in increased discriminative power. A Wilcoxon rank sum test was used to compare group differences. Spearman's correlation was used to evaluate correlation of P-tau 181P and age or MMSE. The data for each assay were analyzed using sigmoidal curve fitting with the GraphPad Prism program (Version 4.01; GraphPad Software, San Diego, CA, USA).
Results
Production process
The homogeneity of the coating process was analyzed by performing an assay with 125 pg/mL of the calibrator peptide on immunoplates obtained from ten different production runs. The median CV (p10-p90) for the positive sample was 3.8% (2.6%-5.8%). The process of blocking and fixation of mAbs on the plates did not affect the P-tau 181P concentration in CSF, as verified for 38 CSF samples (paired t-test on log-transformed values, ps0.145).
The stability of the total kit after a storage period of more than 2 years for different production runs was fully documented. Regression analysis on log-transformed values of concentrations for control samples did not show a statistically significant difference in Ptau 181P concentrations as a function of storage time (kit stability). In addition, the P-tau 181P concentration in CSF (ns2) stored at y808C did not change over a period of more than 2 years, suggesting the possibility of storing CSF samples for extended periods. The CV for these samples amounted to 9.6% and 8.1% (ns19 test runs) (sample stability). Concentrated stock solutions of calibrator peptides were stable for more than 2 years when stored at 2-88C (as compared to storage at y208C). A Wilcoxon matched-pair test revealed no statistical differences between concentrations determined with the frozen or unfrozen calibrator peptides for three control samples. Working solutions of calibrators were repeatedly frozen and thawed (up to 10 times). Regression analysis on log-converted concentrations revealed a nonsignificant decrease for concentrations of 15.6 pg/mL (ps0.129), 62.5 pg/mL (ps0.972) and 125 pg/mL (ps0.069), and a significant decrease for 31.25 pg/mL (ps0.003). A Kruskal-Wallis test revealed that the significant difference for the 31.25 pg/mL was solely due to the values obtained after ten freeze/thaw cycles. It is essential to limit the number of freezing steps for the calibrators.
Analytical performance
Curve fitting Selection of the model for curve fitting was based on experiments with more than ten calibrators over a wide concentration range. The sigmoidal (four-parameter logistic) curves selected provided excellent fits (R 2 s0.99 or higher) and residuals. There was an acceptable linear relation between the concentrations predicted from the calibrator curve or from an independent set of samples and the known concentrations over the complete calibration range of 15.6-500 pg/mL.
Analytical selectivity and specificity
The AT270 mAb recognized tau phosphorylated at threonine 181. No reactivity was obtained using non-phosphorylated peptides or tau phosphorylated at other sites (data not shown). No cross-reactivity with recombinant tau was obtained in quantified CSF in concentration ranges corresponding to healthy and diseased subjects.
CSF handling procedures
The inclusion of several freeze/thaw cycles (ns5), as well as evaluation of the need for a centrifugation step before storage of the CSF, did not result in a significant effect on P-tau 181P concentrations (data not shown). The effect of storage of CSF for a limited period is shown in Figure 1 . No significant difference in P-tau 181P concentration was noted between CSF samples stored for 3 days at room temperature and samples frozen immediately after collection (ps0.913).
Linearity Three different pairs of CSF samples, containing high and low concentrations of P-tau 181P , were combined in different ratios. When the calculated concentrations were plotted against predicted concentrations, no deviation from the bisector could be observed, indicating the absence of matrix effects under the experimental conditions (Figure 2 ).
Repeatability and reproducibility
The inter-and intra-lot variability was tested for low-, medium-, and high-reacting control samples. Results are shown in Table 2 . All CV values (within or between production runs) were lower than 8.5%.
Assay sensitivity and precision
Twelve samples were tested using eight replicates on three plates from five different production runs. The LOD determined was 10-15 pg/mL and LLOQ was 22-28 pg/mL. Figure 3A shows the precision profile of the pooled data for all the plates. Figure 3B shows the method performance chart (bias as a function of CV). The CV was less than 10% for levels between 15.6 and 300 pg/mL. The higher calibrator concentrations showed lower precision. Bias was below 5% for concentrations between 15.6 and 300 pg/mL. Bias may exceed 10% for the highest concentrations. Good to excellent performance was obtained between LLOQ and ULOQ or higher. The validated range was estimated to be between 25 and 250 pg/mL.
Test robustness Different combinations of boundary assay parameters resulted in clear differences in OD output for control samples. However, at the level of P-tau 181P concentrations, differences in boundary assay parameters (see also Table 1 ) remained within the range of random test variation. It was also noted that for the two samples in the linear test range, the CV was less than 10% in all assay parameter combinations tested (data not shown).
Clinical utility
Sample disposition
The study was conducted between March and May 2002. Initially, 223 CSF samples were included in the study (Figure 4) . Ten samples were excluded from statistical analysis since they did not meet the inclusion criteria. Statistical analysis revealed a center effect, with P-tau 181P values generally lower for center 04. Criteria for pooled analysis were defined prospectively in the protocol. As a result, P-tau 181P data from center 04 were omitted in the calculations for cutoff value, sensitivity, and specificity.
Diagnostic characteristics Demographic data and CSF concentrations of P-tau 181P , Ab 1-42, and T-tau in the three diagnostic groups are described in Table 3 . Independent of the center effect mentioned, significantly higher P-tau 181P levels were observed for AD compared to DLB (p-0.001) and CS (p-0.001). No significant difference was observed between the DLB and CS groups (p)0.05). For Ab (data from five centers), significantly lower levels were observed for AD compared to CS (p-0.001) and for DLB compared to CS (p-0.001). No significant difference was observed between DLB and AD groups (ps0.522). For T-tau (data from five centers), significantly higher levels were observed for AD compared to CS (p-0.001) and DLB (p-0.001), while no differences were seen between CS and DLB (ps0.077).
In the present study, P-tau 181P concentrations did not differ as a function of gender. No significant cor- Results are expressed as AUC"SE (number of patients in the analysis, AD/CS or AD/DLB), with significance as compared to the model described in reference (14) . Data were obtained from four centers; only results for which all parameters were available were included in the study. Significance values between parameters are further explained in the Results section. relation between P-tau 181P levels and age was found in CS (ps0.091), AD (ps0.852) or DLB (ps0.125). In the AD and DLB groups, there was no correlation between apolipoprotein E (apoE) genotype and Ptau 181P levels (p)0.05). Furthermore, no significant correlation of P-tau 181P was found with MMSE in AD (rs0.165; ps0.160) and DLB patients (rs0.085; ps0.551). In addition, no effect of blood-brain barrier deficits or gradient on P-tau 181P concentrations was found (unpublished observations obtained from one center).
Classification A ROC curve describes true-positive vs. false-positive rates of a diagnostic test at different cutoff values. The area under the curve (AUC) is considered as a measure of the discriminative power of the test. Table 4 summarizes ROC curves for the differential diagnosis of AD-DLB and AD-CS. For AD vs. CS or DLB, the AUC obtained for T-tau or Ab was not significantly different between analyses with and without center 04 (data not shown). The AUC for Ttau was not statistically significantly different from the AUC for P-tau 181P to discriminate AD vs. DLB (ps0.175), but significantly higher than the AUC for P-tau 181P to discriminate AD vs. CS (ps0.039). The AUC for Ab was not significantly different from the AUC for P-tau 181P to discriminate AD vs. CS (ps0.805), but significantly lower than for P-tau 181P to discriminate AD vs. DLB (p-0.001).
To discriminate between AD and CS, P-tau 181P , T-tau, and Ab 1-42 were entered into different algorithms, including a previously published model combining T-tau and Ab (15) . Using discriminant analysis, a classification tree, or logistic regression, Ptau 181P was removed from this model and diagnostic question, as it did not significantly contribute to the discrimination in this model. As a consequence, the center effect for P-tau 181P was not relevant in this context. The resulting sensitivity, specificity, and overall accuracy of the models are shown in Table 5 . To discriminate AD from CS, the AUC is significantly augmented using the previously described discrimination line (14) compared to T-tau (ps0.021), P-tau 181P (p-0.001) or Ab 1-42 (ps0.010) analyzed individually. By analogy, P-tau 181P , T-tau, and Ab 1-42 were entered into algorithms to discriminate AD from DLB. The point on the P-tau 181P ROC curve at which sensitivity and specificity are maximal for differentiation of AD from DLB was determined as 61 pg/mL. Using this cutoff, a sensitivity of 80% and specificity of 79% were obtained (Table 6 ).
However, in the discriminant analysis model for AD vs. DLB, it is important to note that P-tau 181P alone is the most important variable in the discrimination between AD from DLB. P-tau 181P and Ab remained in the discriminant analysis log-transform model, whereas T-tau was rejected. The most important variable in the classification tree was P-tau 181P , resulting in a cutoff value of 61 pg/mL. P-tau 181P was also the most important variable in the logistic regression model. The cutoff value from the logistic regression model was calculated as 59.4 pg/mL. The resulting sensitivity, specificity, and overall accuracy of the different models are shown in Table 6 .
Discussion
We describe here the analytical and clinical performance of the INNOTEST ᮋ PHOSPHO-TAU (181P) ELISA for quantification of P-tau 181P in CSF. Both phosphorylated and non-phosphorylated tau isoforms have been identified in CSF, fetal human brain, and adult human brain tissue (16, 17) . We found that the quantification of P-tau 181P levels in CSF, using a combination of mAbs AT270 and HT7, was specific; reactivity towards other phosphorylated epitopes and non-phosphorylated tau protein was absent, confirming previously published characterization data (10, 16, 18) . Linearity experiments pointed to a high accuracy level when using undiluted CSF samples. When reproducibility and repeatability experiments were performed (with operators, lot numbers, or test runs as variables), the CV for samples in the assay range were below 15%. Notwithstanding the validated robust assay format, the stability of the kit for at least 13 months (as stated in the kit insert), the relative stability of P-tau 181P in CSF, and the possibility to freeze/thaw calibrator peptides, it is still important to carry out on-site training to obtain the best assay performance. This could avoid center effect(s) as observed in the present study. The production process resulted in a real-time stability of at least 13 months. Extension of this shelf life in the future will be an advantage in clinical trials, since clinical trials sometimes run for more than 2 years before finalization; kits from a single lot could be used to analyze all samples in a specific study. In addition, different CSF handling protocols were evaluated. No effect on P-tau 181P concentrations was noted after centrifugation or storage for up to 3 days at 258C before freezing at y808C. However, repeated freezing and thawing of CSF is not recommended, especially when P-tau 181P is to be analyzed in combination with other biomarkers, such as Ab (9) .
The results of the clinical study extend a previous report (5) on the value of P-tau 181P testing in CSF for discriminating AD from DLB. An overall accuracy level of 80% was observed, which may be difficult to improve on by single-parameter analysis, considering the level of accuracy of clinical diagnosis compared with postmortem findings. The present study also confirmed the reported discrimination line (15) based on the combination of CSF T-tau and Ab 1-42 for discriminating AD from CS. The use of P-tau 181P could not improve this result. However, P-tau 181P was shown to be the most important variable among the different biomarkers in discriminating between AD and DLB, although AUC differences for P-tau 181P compared to T-tau did not reach statistical significance. Notably, when P-tau 181P was used to classify patients instead of T-tau, six additional patients were correctly classified as DLB, whereas Ab 1-42 was shown to have no discriminatory power in distinguishing AD from DLB. Moreover, using different statistical models based on the three biomarkers, P-tau 181P was consistently identified as the most important marker in the discrimination of AD from DLB.
In the study of Mollenhauer et al. (19) , significantly different values were obtained for the comparison between AD and DLB for T-tau and the T-tau/P-tau 181P ratio, but not for Ab , P-tau 181P , or the mixed Ab 1-42 / Ab 40 ratio. Notwithstanding the fact that in this study values for P-tau 181P were lower, albeit not significantly, in the DLB group compared to AD, differences could be explained by the sample size, patients enrolled in the study and/or the homogeneity of the study group. These results will have to be confirmed in larger studies.
A number of sandwich immunoassays that target different phosphorylated epitopes of tau, including Thr181 and Thr231, Thr231 and Ser235, Ser199, Thr231, Thr181, and Ser396, and Ser404 have been developed (20) . Consistently increased levels of P-tau in CSF from patients with AD have been found using these assays (3). In a study directly comparing the diagnostic performance of P-tau 181P , P-tau 199 , and Ptau 231 in the same sets of patients, all three assays performed equally well in the discrimination of AD patients from non-demented subjects. Only minor differences were found when group separation was maximized between AD and FTD using P-tau 231 and between AD and DLB using P-tau 181P controls (21).
Furthermore, there was no difference in the prediction of cognitive decline using each of the P-tau epitopes in patients with mild cognitive impairment (22) . The present study confirms findings published in previous reports that quantification of P-tau could be a useful tool for differential diagnosis of neurodegenerative disorders (5, 21, 23) .
Numerous published reports have already mentioned the need for a multiparametric approach in the domain of AD diagnosis. As in other areas of medicine, CSF markers for AD may not be used in isolation, but can provide added value to the information obtained from clinical examination, brain-imaging techniques (e.g., single photon emission CT and MRI), and routine CSF biochemical analysis. It has already been concluded that T-tau, Ab 42 , and P-tau 181P , when used as adjuncts to clinical diagnosis, have the potential to help differentiate AD from some difficult differential diagnoses (e.g., normal aging, depressive pseudo-dementia, Parkinson's disease, progressive supranuclear palsy, and alcoholic dementia) (24) and amyotrophic lateral sclerosis (25) . The present study confirms that better diagnostic performance compared to single-parameter analysis can be obtained for the discrimination of CS and AD using T-tau and Ab (15) . The P-tau 181P /T-tau ratio can discriminate patients with Creutzfeldt-Jakob disease from those with other neurological disorders, including AD and FTD (26, 27) . Similar cutoff values were published for discrimination of AD patients from controls by Lewczuk et al. (28) . Higher diagnostic accuracy was reported for the combination of low CSF Ab 1-42 and high P-tau 181P in differentiating early-onset AD from FTD (6) and for differentiation of AD and healthy controls (29) . Identical results with respect to Ab 1-42 and T-tau for comparison between CS, AD, and DLB have been published recently (30) .
Individual markers have been demonstrated to be of potential clinical use in the identification of early AD. Further improvement will likely be achieved by the creation of a complex model that includes several biomarkers to adequately describe this phenomenon. Published results on the diagnostic capacity of CSF markers come from studies of clinically diagnosed patients. This means that the diagnostic performance of CSF markers cannot be higher than the accuracy of the clinical diagnostic criteria used. Owing to this diagnostic uncertainty and the heterogeneity of the disease process, it may well be beneficial to select, validate, and implement an algorithm that is based on a combination of biomarkers to reduce the overlap between different diagnostic groups.
The data available at present must be used with caution when building ''optimistic'' models or algorithms to estimate the performance in terms of clinical accuracy. The clinical accuracy levels in the present paper are mentioned as tentative estimates and not as a final conclusion for a particular application. The model should be validated and confirmed using a larger number of samples.
A limitation of the present study is, of course, the small cohort with the risk of selection bias and insufficient power to draw firm conclusions. The concentration and cutoff values provided can be used for guidance. However, given the center effect observed, laboratories using this marker in a clinical setting should first establish local reference ranges.
In conclusion, these data show that the INNOTEST ᮋ PHOSPHO-TAU (181P) is a robust and reliable assay that can potentially be used in a diagnostic context. It will be important to accumulate data from longitudinal studies to interpret results of the biomarkers together with imaging and neuropsychological markers.
